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market also has its limitations (10), and 
questions concerning the efficacy of new 
drugs in routine clinical use cannot be an-
swered by randomised clinical trials but 
only through the long-term observation of 
large representative groups of patients in a 
variety of clinical settings. Consequently, 
registries have been proposed for the long-
term surveillance necessary to assure the 
safe and rational clinical use of the existing 
and future treatments available to rheuma-
tologists (11).
GISEA (the Italian Group for the Study of 
Early Arthritis, see http://www.registrogi-
sea.com) involves 21 Italian clinical centres 
n	 INTRODUCTION
Registries have been developed by a number of Rheumatology Societies in 
order to provide a clear-cut database con-
cerning the occurrence of minor and major 
adverse events in patients treated with bio-
logical drugs. Although it is indisputable 
that randomised trials are useful for meas-
uring efficacy under controlled conditions,
they have well-known shortcomings in 
terms of the discovery of rare or late de-
veloping adverse events (1-9). Relying on 
the passive voluntary reporting of adverse 
events after a drug is introduced on the 
RIASSUNTO
Il registro GISEA è una banca dati istituita dal Gruppo Italiano per lo Studio di Early Arthritis (GISEA) nel 
2008 e fi nanziata dall’associazione italiana dei pazienti reumatici (ANMAR-ONLUS). Il suo scopo è quello di 
fornire un follow-up a lungo termine di pazienti con malattie reumatiche che sono trattati con agenti biologici. 
In questo documento descriviamo il disegno e la metodologia usati per raccogliere i dati dei pazienti. Registria-
mo informazioni demografi che, decorso della malattia, cambiamenti di trattamento, includendo le ragioni del 
cambiamento e la durata di ciascuna terapia, le terapie concomitanti e gli eventi avversi. Queste informazioni 
sono disponibili ai membri del gruppo di studio attraverso un’interfaccia basata su web che consente richieste 
e presentazione di dati numerici, oltre a una rappresentazione grafi ca per apprezzare le tendenze. Quattordici 
centri italiani di reumatologia hanno partecipato contribuendo con pazienti alla banca dati. Al momento della 
scrittura di questo testo la banca dati include 5145 pazienti, prevalentemente donne (72%) e con un’età media 
di 53 anni (intervallo 16-88).
Diagnosi: 3494 (67,9%) con artrite reumatoide, 833 (16,2%) con artrite psoriasica, 493 (9,6%) con spondili-
te anchilosante, 307 (5,9%) con spondiloentesoartrite indifferenziata, 14 (0,3%) con artrite enteropatica e 4 
(0,1%) con spondilite successiva ad una artrite reattiva. I trattamenti biologici hanno incluso etanercept, infl i-
ximab, anakinra, adalimumab, abatacept, rituximab e tocilizumab. I pazienti sono stati seguiti per 10 anni; sul 
totale degli arruolati, 1927 pazienti (35.8%) sono in follow-up da almeno 3 anni. Nel registro GISEA sono stati 
osservati in tutto 2926 eventi avversi, con 1171 (22%) pazienti che ne hanno riportato almeno uno. Auspichia-
mo che l’analisi di questi dati accumulati consenta di approfondire la critica fase precoce dell’artrite reumatoide 
e renda possibile l’identifi cazione di profi li clinici che predicano la responsività alla terapia.
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and practices and has the aim of investigat-
ing the evolution of (poly)arthritides from 
their earliest manifestations by monitoring 
disease progression during treatment and 
promoting early diagnosis and treatment. 
Fourteen of the twenty one GISEA centres 
have contributed to build a registry whose 
aim is to collect the clinical and labora-
tory data of patients affected by inflamma-
tory arthropathies treated with biological 
agents in order to evaluate the number and 
prevalence of adverse events related to their 
long-term use, establish the proportion of 
responders and their survival on therapy, 
identify the predictive factors and/or co-
morbidities modifying the outcome of bio-
logical therapy, and ascertaining the major 
risk factors for an inadequate response to 
the most widely used biological drugs.
This paper describes the design and meth-
odology of the GISEA registry of Italian 
patients with (poly)arthritides treated with 
biological agents, which includes all of 
the patients monitored in GISEA referral 
centres regardless of the duration of their 
disease, and the preliminary data obtained.
n	 PATIENTS AND METHODS
GISEA registry
In 2008, with the funding and support of 
the Italian Association of Rheumatic Pa-
tients (ANMAR - ONLUS), our group 
established a national database for moni-
toring the efficacy and safety of TNFα-
blocking therapies, which were initially 
only used to treat early aggressive rheu-
matoid arthritis (RA). Subsequently, as 
new biological therapies entered the Italian 
market and their therapeutic indications 
were extended to other diseases, we also 
included patients taking these drugs for 
other types of arthritides. The participating 
centres represent a mix of small and large 
clinics or departments.
Survival on therapy is defined as the 
number of months from baseline (first ad-
ministration) to the time of this analysis or 
treatment discontinuation (to switch to an-
other drug or when the patients were lost to 
follow-up).
The protocol does not pre-establish the 
patients’ assignment to a study drug. The 
drugs are prescribed in accordance with 
their Summaries of Product Characteristics 
(SmPCs) on the basis of the physicians’ in-
dependent judgement and current clinical 
practice, thus clearly separating the deci-
sion to prescribe a certain treatment from 
inclusion in the registry. The patients do 
not undergo any additional diagnostic or 
monitoring procedures.
Study population
The patients consecutively attending each 
GISEA referral center are enrolled if they 
are diagnosed as having RA, psoriatic ar-
thritis (PsA), ankylosing spondylitis (AS), 
enteroarthritis, undifferentiated spondylo-
arthritides) (12, 14). All of the subjects en-
tered in the registry are required to meet the 
eligibility criteria and provide written con-
sent to the use of their personal and health-
related data.
Inclusion criteria
Patients are enrolled in the GISEA regis-
try on the basis of the following inclusion 
criteria:
• an age of >18 years;
• written informed consent given before 
enrolment;
• a diagnosis of chronic inflammatory ar-
thropathy as specified above;
• treatment with conventional disease-
modifying anti-rheumatic drugs 
(DMARDS) and/or biological agents in 
accordance with current national and in-
ternational guidelines (15, 18) and usual 
standards of good clinical practice.
Exclusion criteria
Patients are excluded from the registry on 
the basis of the following criteria:
• an age of <18 years;
• refusal to participate in the study or sign 
the informed consent form;
• the presence of any of the contraindica-
tions listed in each drug’s SmPC. 
Information retrieval
When patients enter the registry, informa-
tion is collected concerning their demo-
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graphic (age, gender, ethnicity, and present 
and past smoking status) and baseline dis-
ease characteristics, including diagnosis, 
duration and functional class, previous 
treatments (conventional DMARDS and/or 
biological agents), comorbidities, and the 
extra-articular manifestations of their rheu-
matic disease.
Subsequently, data concerning treatment, 
disease activity, response to therapy and ad-
verse events are collected at pre-specified 
intervals from the time of diagnosis and 
stored by the investigator in a web-based 
limited-access database (Tab. I) (loaded on 
http://www.registrogisea.com) that allows 
the graphic and tabular representation of 
current and past disease activity and medi-
cation. Access to the database is protected 
by an identification procedure: the inves-
tigators are given their own user-IDs and 
passwords.
After signing a written informed consent 
form, each registry patient is assigned a 
centre-scpecific subject number, and the 
investigators can only access the relating to 
their own patients.
The database was created by CD Pharma 
Group S.r.l. (Milan, Italy), which is also re-
sponsible for data management.
Assessment of disease activity 
and treatment response
Disease activity is measured at baseline, 
six and 12 months after entry, and every 
year thereafter. All of the procedures de-
scribed below (clinical, laboratory and 
imaging techniques) fall within the usual 
clinical management of rheumatic pa-
tients receiving biological therapy as per 
the current national and international 
guidelines.
Disease activity and treatment response are 
assessed using internationally established 
criteria.
a) Rheumatoid arthritis (Tab. Ia). The pa-
tients are monitored by means of: 
1) the Disease Activity Score (DAS-
28) (19); 
2) the individual components of the 
DAS-28: swollen joint count (SJC, 
0-28), tender joint count (TJC, 
0-28), erythrocyte sedimentation 
rate (ESR), and patient-reported 
global health status (GH, VAS); 
3) the simplified disease activity index 
(SDAI) and clinical disease activity 
index (CDAI) (20, 21); 
4) the American College of Rheuma-
tology (ACR) core set of outcome 
measures for rheumatoid arthritis 
(22); and 
5) the Health Assessment Question-
naire (HAQ) (23) in order to moni-
tor functional disability.
b) Ankylosing spondylitis, psoriatic ar-
thritis and undifferentiated arthritis 
(Tab. Ib). As appropriate for each case, 
the patients are monitored by means of: 
1) swollen joint count (SJC, 0-66) and 
tender joint count (TJC, 0-68), to in-
clude the cervical spine, ankles, feet 
Table I - giSea registry: data collected at each time-point for ra patients (a) 
and Spa patients (B).
(A) Baseline visit (T0) Follow-up visits
informed consent X
Demographical data X
inclusion/exclusion criteria X
anamnesis X X
Physical examination X X
Current therapy X X
Laboratory tests, eSr, CrP X X
rF, anti-CCP X X
ana, anti-dsDna, anti-ena X X
HaQ X X
DaS 28 X X
adverse events X X
(B) Baseline visit (T0) Follow-up visits
informed consent X
Demographic data X
inclusion/exclusion criteria X
anamnesis X X
Physical examination X X
Current therapy X
Laboratory tests, eSr, CrP X X
rF X X
ana, anti-dsDna, anti-ena X X
TJC (0-68), SJC (0-66) X X
BaSDai X X
BaSFi X X
MaSeS index X X
PaSi X X
adverse events X X
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Figure 1 - Distribu-
tion of the 5145 gi-
Sea patients among 
the 14 participating 
centres as of March 
2010.
and the distal interphalangeal joints 
of the hands and feet; 
2) the assessment in the Ankylosing 
Spondylitis coreset (ASAS) (24); 
3) the Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI) 
(25), the Bath Ankylosing Spondyli-
tis Functional Index (BASFI) (26), 
the Bath Ankylosing Spondylitis 
Metrology Index (BASMI) (27), the 
Maastricht Ankylosing Spondylitis 
Enthesitis Score (MASES) (28), and 
the Psoriasis Area Severity Index 
(PASI) (29).
The laboratory data collected for each 
rheumatic patient are rheumatoid factor, 
Creactive protein, anti-cyclic-citrullinated 
protein antibodies, and the erythrocyte sed-
imentation rate.
All of the patients undergo the screening 
and follow-up procedures recommended in 
the current guidelines, including Tb, HBV, 
HCV screening and chest and pathological 
joints radiographs.
Safety
All adverse drug reactions were recorded 
and classified on the basis of their severity 
and causal relationship with the adminis-
tered drugs.
Pharmacoeconomic data
Health-related quality of life (HRQoL) is 
assessed at baseline and every follow-up 
time-point using the EuroQoL (EQ-5D) 
questionnaire, a simple self-administered 
instrument that is designed to measure 
general health outcomes by generating a 
5- domain profile (mobility, self-care, anx-
iety/depression, usual activities and pain/
discomfort) and an overall health-related 
quality of life score measured by means of 
a visual analogue scale (VAS); it is also a 
useful tool to derive cost/utility analyses. 
The EQ-5D is one of the most extensively 
validated measures for evaluating overall 
HRQoL in patients with inflammatory ar-
thritis (30).
Negative effects on the working productiv-
ity of both patients and caregivers is meas-
ured as the amount of working time lost 
due to the disease.
Ethical aspects
This study is being performed in accord-
ance with the principles of the Declaration 
of Helsinki and European and local rules 
of good clinical practice (GCP). All of the 
the procedures are part of the usual care 
of patients. The study was assessed and 
approved by the Ethics Committee and a 
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Table II - enrolment diagnosis of giSea patients as of March 2010.
Disease No. of patients Percentage of total 
patients
Mean age at 
diagnosis, years
Mean BMI
enteropathic arthritis 14 0.3 43 27.78
Psoriatic arthritis 833 16.2 49 26.96
rheumatoid arthritis 3494 67.9 53 25.34
reactive arthritis 4 0.1 60 n.d.*
enthesopathic arthritis 64 1.2 47 28.33
ankylosing spondylitis 493 9.6 43 25.48
Undifferentiated spondylo-arthritis 243 4.7 47 26.77
Total 5145 100
*not determined.
Table III - Concurrent therapy.
Therapy Patients (%)
DMARDs
azathioprine 53 (0.8)
Cyclosporine 281 (4.2)
Hydroxychloroquine 646 (9.8)
Leflunomide 724 (10.9)
Methotrexate 4294 (64.9)
Penicillamine 2 (-)
Sulfasalazine 533 (8.1)
gold salts 81 (1.2)
Corticosteroids
Betamethasone 37 (0.7)
Deflazacort 106 (2.1)
Methylprednisolone 3180 (62.0)
Prednisone 1809 (35.2)
Table IV - First line biological therapy taken by 
giSea as of March 2010.
Biological 
therapy
No. of patients %
abatacept 18 0.4
adalimumab 1233 25.8
anakinra 88 1.8
etanercept 1917 40.1
infliximab 1462 30.5
rituximab 68 1.4
Total 4786 100
written consent form is signed by each pa-
tient upon entry in the registry.
n	 RESULTS
The GISEA registry is the largest existing 
database in Italian rheumatic patients.
As of March 2010, 5.145 patients had been 
enrolled by the 14 GISEA centres (Fig. 1) 
of whom 1.927 (35.8%) had been treated 
for at least three years.
Demographics, diagnosis 
and comorbidities
The database includes 3.494 patients 
(67.9%) with RA, 833 (16.9%) with PsA, 
493 (9.6%) with AS, and 307 (5.9%) with 
undifferentiated spondylo-entheso ar-
thritides (Tab. II). The female/male ratio is 
2.54 (3703:1457), and the majority of pa-
tients are aged 46-65 years (overall mean 
age 53 years, range 16-88 years). The most 
frequent comorbidities are hypertension 
(1.091 patients, 20.6%), thyroid diseases 
(416, 7.9%), and ischemic cardiopathy, 
gastrointestinal illnesses (diverticuli, gas-
tritis, irritable colon disease, gastroesopha-
geal reflux disease) and diabetes (nearly 
270 patients each, about 5%). The pattern 
of comorbidities observed in our cohort 
seems to resemble those reported in other 
RA patients populations treated with bio-
logical agents (31).
Conventional and biological therapies
Table III shows that methotrexate is the 
most frequently chosen DMARD to com-
bine with biological therapy (4.294 pa-
tients, 64.9%), followed by leflunomide 
(724, 10.9%), hydroxychloroquine (646, 
9.8%) and sulfasalazine (533, 8.1%). Of 
the corticosteroids, methylprednisolone is 
concomitantly prescribed for 3.180 patients 
(62%) and prednisone for 1.809 (35.2%).
As first-line biological therapy, 1.917 pa-
tients (40.1%) received etanercept, 1.462 
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Figure 2 - Disease activity assessment (DaS-28) in 3494 giSea patients with ra treated with 
biological agents in giSea database (mean values). 
(30.5%) infliximab and 1.233 (25.8%) 
adalimumab (Tab. IV). As expected, data 
on patients treated with Etanercept, Inf-
liximab and/or Adalimumab predominate 
because they were introduced first into 
clinical practice. However, the number of 
Table VI - reason for stopping biological therapy 
in giSea patients as of March 2010.
Reason %
Death 1.2
Drop out/lost to follow-up 13.2
adverse event 29.8
Primary drug inefficacy 32.9
Secondary loss of efficacy 13.8
remission 23.6
other 5.5
Table V - Treatment survival (months).
First treatment Second treatment
No. of patients Mean ± SD No. of patients Mean ± SD
abatacept 17 4.59±6.20 7 10.3±4.54
adalimumab 977 12.9±14.4 126 23.5±15.7
anakinra 73 15.9±19.4 14 31.7±20.6
etanercept 1349 13.8±16.9 255 27.9±18.4
infliximab 1079 16.5±21.3 63 19.6±15.5
rituximab 48 3.48±6.87 19 18.6±17.5
patients treated with more recent therapies 
is increasing.
All of the drugs that have been on the mar-
ket for more than five years (anakinra, inf-
liximab, etanercept and adalimumab) show 
comparable survival on treatment (Tab. V), 
which is longest in the case of etanercept 
and infliximab although the difference is 
not statistically significant. This trend is 
quite in line with previous published data 
from other European registries (32, 33). 
When used as first-line therapy, the mean 
duration of treatment with etanercept is 
13.8 months (1.349 patients) and that of 
infliximab is 16.5 months (1.079 patients); 
when used as second-line therapy, etaner-
cept once again shows the longest treat-
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ment survival (a mean treatment duration 
of 27.9 months in 255 patients).
Table VI shows the main reasons for stop-
ping biological treatment: drug inefficacy 
in 32.9% of the cases, adverse events in 
29.8%, secondary inefficacy (loss of effi-
cacy) in 13.8%, drop out/lost to follow-up 
in 13.2%, and disease remission in 3.6%. 
The low percentage of remission is prob-
ably due to the large number of patient 
with late disease and multiple comorbidi-
ties constituting the “real life” population 
enrolled in the study. Overall, the observed 
rates of treatment discontinuation are com-
parable with those reported in other regis-
tries, ranging between 21-38% for adverse 
events (34, 32) and between 22-36% for 
inefficacy (34, 35).
On the basis of the trend of the DAS-28 
scores in the RA patients, disease activ-
ity was significantly reduced during the 
first six months of treatment, and then 
remained generally stable during seven 
years of follow-up (Fig. 2). In the AS 
patients, the BASDAI scores also sig-
nificantly decreased during the first six 
months of treatment, but then fluctuated 
more over time (Fig. 3). One possible ex-
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Figure 3 - Disease activity assessment (BaSDai score) in giSea patients with spondylo-arthri-
tis treated with biological agents (mean values).
planation for this observation can be re-
lated to the demonstrated efficacy of anti-
TNF agents on inflammatory bone edema 
in AS patients, which leads to a signifi-
cant improvement in signs and symptoms 
during the first months of therapy. On the 
contrary, anti-TNF agents do not seem to 
inhibit the bone formation associated with 
AS (36, 38), although further research is 
clearly needed to assess their full impact 
on radiographic progression in AS. How-
ever, the interpretation of these data may 
be limited by the use of mean values in the 
absence of stratification by drug or base-
line disease activity.
A total of 2.926 adverse events have so far 
Table VII - adverse events in giSea patients as of 
March 2010.
Adverse event N %
Cardiovascular events 93 3.25
infections 1161 39.68
neoplasms 48 1.64
Biological reactions 249 8.51
increased transaminases 132 4.51
other 1241 42.41
Total (all) 2926 100
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been observed, with 1.171 patients (22%) 
reporting at least one adverse event. Infec-
tions have been reported by 1.161 patients 
(39.68%) (Tab. VII).
n	 CONCLUSIONS
With 5.145 treated patients, the GISEA da-
tabase that we have constructed and main-
tained over the last two years provides the 
largest Italian system for monitoring the 
safety and clinical efficacy of biological 
therapies, and survival on treatment in a 
number of rheumatic diseases. GISEA is 
an important resource for tracking the evo-
lution of disease activity in treated patients 
and, as it provides access to “real life” 
data concerning therapeutic outcomes in 
patients with long-standing diseases and 
various comorbidities that may affect the 
efficacy of treatment, our registry provides 
a powerful and useful means of improving 
patient management. 
To this end it entered into the METEOR 
network (www.meteorfoundation.com; 
http://meteorfoundation.com/Portals/0/
Current%20Country%20Leads.pdf) pro-
viding METEOR a substantial percentage 
of all the patients registered at the Inter-
national Level. It is clear that the chance 
of confronting ourselves with other clini-
cal approaches worldwide will represent 
a challenge but certainly also an enrich-
ment.
The database also offers insights into the 
cost effectiveness of these therapies and al-
lows the development of rational and cost-
effective strategies for their use.
Prescription practices are influenced by 
efficacy, safety, physician preferences and, 
increasingly, also pharmaco-economic 
considerations. The relatively high cost of 
biological therapies in comparison with 
traditional DMARDS justifies close scru-
tiny of their efficacy and safety not only 
in the carefully selected populations of 
controlled clinical trials, but also in rou-
tine practice (something that is becoming 
increasingly important to healthcare man-
agement agencies).
We are also confident that a full analysis of 
our data will provide insights into the criti-
cal early phase of rheumatic diseases and 
make it possible to identify clinical profiles 
that predict treatment responsiveness.
SUMMARY
The GISEA registry is an independent database that was established by the Italian Group for the Study of Early 
Arthritis (GISEA) in 2008, funded by the Italian Association of Rheumatic Patients (ANMAR - ONLUS). In line 
with the network’s epidemiological strategy, the initial protocol was designed to collect long-term follow-up 
data concerning patients with rheumatic diseases treated with biological agents in order to investigate the real-
world characteristics in terms of disease activity, comorbidities and survival on treatment. We here describe the 
design and methodology used to collect patient data. Information concerning demographics, disease activity, 
treatment changes (including the reasons for changing and the duration of each therapy), concomitant thera-
pies and adverse events is available to all the members of the study groups by means of a web-based interface 
that allows queries and the presentation of numerical data, as well as graphics to illustrate trends. Fourteen 
Italian rheumatology centres have contributed patients to the database which, at the time writing, includes 
5145 patients (72% women) with a mean age of 53 years (range 16-88). The initial diagnoses were rheumatoid 
arthritis (3494 patients, 67.9%), psoriatic arthritis (833, 16.2%), ankylosing spondylitis (493, 9.6%), undiffer-
entiated spondylo-arthritides (307, 5.9%), enteropathic arthritis (14, 0.3%) and spondylitis following reactive 
arthritis (4, 0.1%). These patients have been followed for up to 10 years, and 1927 (35.8%) have been treated 
for at least three years. The biological treatments received include etanercept, infliximab, anakinra, adalim-
umab, abatacept, rituximab and tocilizumab. A total of 2926 adverse events have been observed, with 1171 
patients (22%) reporting at least one.
Analysis of the accumulated data will provide insights into the critical early phase of the studied arthritides, 
and enable us to identify the clinical and laboratory profiles that may predict responsiveness to a specific 
therapy.
Parole chiave: Farmaci biologici, studio osservazionale, pratica clinica.
Key words: Biological agents; observational study; real-world practice.
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